The estimated Net Worth of Jan Johannessen is at least $1.01 Million dollars as of 9 February 2023. Mr. Johannessen owns over 1,732 units of Twist Bioscience Corp stock worth over $515,286 and over the last 21 years he sold TWST stock worth over $60,725. In addition, he makes $429,744 as Independent Director at Twist Bioscience Corp.
Sign up
Mr. Johannessen TWST stock SEC Form 4 insiders trading
Jan has made over 6 trades of the Twist Bioscience Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,732 units of TWST stock worth $45,829 on 9 February 2023.
The largest trade he's ever made was exercising 5,000 units of Twist Bioscience Corp stock on 16 February 2022 worth over $70,000. On average, Jan trades about 1,099 units every 32 days since 2003. As of 9 February 2023 he still owns at least 11,616 units of Twist Bioscience Corp stock.
You can see the complete history of Mr. Johannessen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jan Johannessen biography
Jan Johannessen serves as Independent Director of the Company. Mr. Johannessen currently serves as an advisor to iGlobe Partners, a venture capital company. Mr. Johannessen served as Chief Operating Officer and Secretary at Conexant Systems, LLC, a semiconductor company, from May 2013 to August 2017 and also served as its Chief Financial Officer from May 2013 to May 2016 and as its Chief Executive Officer from May 2016 to August 2017. Mr. Johannessen served as Chief Financial Officer and Secretary at REC Silicon ASA, a company listed on the Oslo stock exchange from August 2008 to May 2013. He served as Interim Chief Executive Officer and President at Lattice Semiconductor Corporation, a publicly traded company, from May 2008 to August 2008 and as Chief Financial Officer and Secretary at Lattice Semiconductor Corporation from December 2003 to May 2008. Mr. Johannessen holds a B.S. in Business from the University of Houston, and a MBA in International Business from Arizona State University. Our board of directors believes that Mr. Johannessen brings extensive executive experience in the technology industry and financial and accounting expertise, which qualifies him to serve as one of our directors.
What is the salary of Jan Johannessen?
As the Independent Director of Twist Bioscience Corp, the total compensation of Jan Johannessen at Twist Bioscience Corp is $429,744. There are 9 executives at Twist Bioscience Corp getting paid more, with Emily Leproust having the highest compensation of $8,126,160.
How old is Jan Johannessen?
Jan Johannessen is 63, he's been the Independent Director of Twist Bioscience Corp since 2018. There are 4 older and 18 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
What's Jan Johannessen's mailing address?
Jan's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Twist Bioscience Corp
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell und Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
What does Twist Bioscience Corp do?
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
What does Twist Bioscience Corp's logo look like?
Complete history of Mr. Johannessen stock trades at Lattice Semiconductor und Twist Bioscience Corp
Twist Bioscience Corp executives and stock owners
Twist Bioscience Corp executives and other stock owners filed with the SEC include:
-
Emily Leproust,
Chairman of the Board, President, Chief Executive Officer -
James Thorburn,
Chief Financial Officer -
Patrick Finn,
Chief Commercial Officer -
Dr. Emily Marine Leproust Ph.D.,
Co-Founder, Chairman, Pres & CEO -
Patrick Weiss,
Chief Operating Officer -
James M. Thorburn,
Chief Financial Officer -
Dr. Patrick John Finn Ph.D.,
Chief Commercial Officer -
Mark Daniels,
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary -
Dr. William Charles Banyai Ph.D.,
Sr. VP of Advanced Devel., GM of Data Storage & Director -
Jan Johannessen,
Independent Director -
Nelson Chan,
Independent Director -
Robert Ragusa,
Independent Director -
Keith Crandell,
Independent Director -
Robert Chess,
Lead Independent Director -
Xiaoying Mai,
Independent Director -
Nicolas Barthelemy,
Independent Director -
William Banyai,
Director -
Paula Green,
Vice President of Human Resources -
Bill Peck,
Chief Technology Officer -
Erin Smith,
Senior Vice President - Government affairs and Public policy -
Martin Kunz,
Senior Vice President - Operation -
Patrick Weiss,
Chief Operating Officer -
Tracey Mullen M.B.A.,
Sr. VP of Operations -
Paula Green,
Sr. VP of HR -
Dennis Cho,
Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer -
Kevin B. Yankton,
VP & Chief Accounting Officer -
Mark Daniels Esq.,
Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. -
Dr. Aaron K. Sato,
Chief Scientific Officer & Chief Scientific Officer of BioPharma -
Siyuan Chen,
Chief Technology Officer -
Adam Laponis,
Chief Financial Officer -
Alpha Fund L.P. Ever,
10% owner -
Fred B Craves,
Director -
Venture Partners Viii, Llca...,
-
Melissa A. Starovasnik,
-
Dennis Cho,
See Remarks -
Kevin Bruce Yankton,
Chief Accounting Officer -
Robert F. Werner,
Chief Accounting Officer